GlassScriptPhysician profile
Rabina Malik-Hamirani
NPI 1831159896
$5,503.14
in general payments reported to CMS, 2019-2025
30 companies · $782 in 2025
The $782 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $340 · 2021: $576 · 2022: $1,046 · 2023: $876 · 2024: $906 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.64 |
| Education | $291.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $741.25 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $610.97 | 2019-2023 | Veltassa |
| Amgen INC. | $598.92 | 2019-2023 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $584.93 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $559.51 | 2019-2025 | Jynarque, Rexulti |
| Akebia Therapeutics INC | $531.08 | 2019-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $491.69 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $221.62 | 2023-2025 | |
| Alkermes, INC. | $204.98 | 2019-2025 | Vivitrol, Vivitrol |
| Mallinckrodt Hospital Products INC. | $139.55 | 2021-2024 | Terlivaz, Acthar |
| Novo Nordisk INC | $104.15 | 2024-2025 | Ozempic, Rivfloza |
| Aurinia Pharma U.S., INC. | $98.59 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $74.95 | 2021-2023 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.70 | 2025 | Caplyta |
| Lilly USA, LLC | $63.69 | 2019-2024 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.11 | 2019-2020 | |
| Corcept Therapeutics | $44.77 | 2025 | Korlym |
| Mylan Specialty L.P. | $43.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $39.54 | 2025 | Ultomiris |
| Baxter Healthcare | $36.56 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.94 | 2024 | |
| Indivior INC. | $20.68 | 2024 | Sublocade |
| Ultragenyx Pharmaceutical INC. | $20.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.29 | 2023 | Gattex |
| Calliditas Therapeutics US INC. | $18.75 | 2023 | Tarpeyo |
| Genzyme Corporation | $18.70 | 2023 | |
| Glaxosmithkline, LLC. | $17.13 | 2022 | |
| Shire North American Group INC | $16.10 | 2019 | |
| Sanofi Pasteur INC. | $14.98 | 2020 | |
| Allergan, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabina Malik-Hamirani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.